Career history of Mark D. Matteucci
Former positions of Mark D. Matteucci
| Companies | Position | Start | End |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 1987-12-31 | 1998-12-31 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Chief Tech/Sci/R&D Officer | 2002-07-31 | - |
| Corporate Officer/Principal | 2002-07-31 | - |
Training of Mark D. Matteucci
| Massachusetts Institute of Technology | Undergraduate Degree |
| The University of Colorado | Doctorate Degree |
Statistics
International
| United States | 5 |
Operational
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Finance | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
- Stock Market
- Insiders
- Mark D. Matteucci
- Experience
